# Culmerciclib in HR+/HER2+ Advanced Breast Cancer

> **NCT07732491** · PHASE2 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 35 (estimated)

## Conditions studied

- Breast Cancer
- Metastastic Breast Cancer
- HER2+ Advanced Breast Cancer

## Interventions

- **DRUG:** Culmerciclib

## Key facts

- **NCT ID:** NCT07732491
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-01
- **Primary completion:** 2028-12-31
- **Final completion:** 2035-12-31
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07732491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07732491, "Culmerciclib in HR+/HER2+ Advanced Breast Cancer". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07732491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*